Alphatec (ATEC) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATEC shares.
View ATEC analyst ratings or view top-rated stocks.

7 brokers have issued 12-month target prices for Alphatec's stock. Their ATEC share price forecasts range from $12.00 to $32.00. On average, they expect the company's share price to reach $22.00 in the next year. This suggests a possible upside of 69.6% from the stock's current price.
View analysts price targets for ATEC or view top-rated stocks among Wall Street analysts.

Alphatec's stock was trading at $12.35 at the start of the year. Since then, ATEC shares have increased by 5.0% and is now trading at $12.97.
View the best growth stocks for 2023 here.

Alphatec saw a increase in short interest in September. As of September 15th, there was short interest totaling 6,700,000 shares, an increase of 5.5% from the August 31st total of 6,350,000 shares. Based on an average trading volume of 1,230,000 shares, the short-interest ratio is currently 5.4 days. Currently, 8.9% of the company's shares are sold short.
View Alphatec's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ATEC earnings forecast.

Alphatec Holdings, Inc. (NASDAQ:ATEC) posted its quarterly earnings data on Thursday, August, 3rd. The medical technology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.13. The medical technology company had revenue of $116.92 million for the quarter, compared to analyst estimates of $110.18 million.

ETFs with the largest weight of Alphatec (NASDAQ:ATEC) stock in their portfolio include Jacob Forward ETF (JFWD), Innovator IBD 50 ETF (FFTY), SPDR S&P Health Care Equipment ETF (XHE) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

Alphatec issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $462.00 million-$462.00 million, compared to the consensus revenue estimate of $451.05 million.

19 employees have rated Alphatec Chief Executive Officer Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among the company's employees. 63.0% of employees surveyed would recommend working at Alphatec to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alphatec investors own include Macrocure Ltd. - Ordinary Share (MCUR), LinnCo (LNCOQ), California Resources (CRC), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), (GBSN) (GBSN), Idera Pharmaceuticals (IDRA), Athersys (ATHX), Anavex Life Sciences (AVXL) and BioCryst Pharmaceuticals (BCRX).

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

Shares of ATEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATEC stock can currently be purchased for approximately $12.97.

Alphatec (NASDAQ:ATEC) has a market capitalization of $1.56 billion and generates $421.81 million in revenue each year. The medical technology company earns $-152,150,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

The company employs 705 workers across the globe.

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The official website for the company is www.atecspine.com. The medical technology company can be reached via phone at (760) 431-9286, via email at ir@alphatecspine.com, or via fax at 800-922-1356.